Researchers Set Sights on New Ovarian Cancer Treatment Strategies

Despite breakthrough treatments for high-grade serous ovarian cancer, about 80 percent of patients relapse within two years, often resistant to treatment. The good news is that Dana-Farber scientists are pursuing multiple avenues of research that very well may improve outcomes. “A number of patients develop progressive disease at a later point, potentially indicating that a … Read more

Patient-Derived Ovarian Cancer ‘Organoids’ Aid Precision Oncology Research

The time may not be far off when the treatment for a person’s ovarian cancer can be tailored to their malignancy using drugs selected by testing on “organoids” — miniature 3-D clusters of cancer cells grown from a patient’s own tumor cells. Although ovarian organoid tests are not yet being used to guide treatment decisions, … Read more

Dana-Farber Patient Benefits From ‘Growing Toolbox of Treatments’

When Dana-Farber launched its new Center for BRCA and Related Genes in August 2020, it was with patients like Janice Dolnick in mind. Dolnick’s cancer journey had already been a long one before she came to Dana-Farber for a consult in 2018. Over the previous 21 years, she’d been through two rounds of breast cancer … Read more

Combination Therapy Working Well for Patient with Cervical Cancer in Clinical Trial

Just as the COVID-19 pandemic was sending entire states into lockdown, Jill Bailey learned that her metastatic cervical cancer was beginning to break free of the grip of chemotherapy. It was March 2020. Scans showed that Bailey’s metastatic tumors, which had shrunk in response to chemotherapy and another drug, were slowly starting to grow. A … Read more

Study Uncovers Potent Immunotherapy Approach to Ovarian Cancer Treatment

Immune therapies declare open season on cancer, rousing immune system cells to take up an attack on tumors. But which immune cells join the hunt, which sit it out, and what happens within immune cells that causes them to go on the offensive? Such questions are especially relevant when immunotherapies show only limited effectiveness against … Read more

For Patient with Endometrial Cancer, Immunotherapy Proves the Perfect Move

As a designer of fantasy-style board games, Kate Beckett knows that timing and chance can play important roles in a player’s survival. Living with metastatic endometrial cancer, she has proof both can also be helpful in the real world. Beckett had already endured a hysterectomy, chemotherapy, radiation, and a serious kidney infection during six years … Read more

Young Investigators Use Patient Samples for Cancer Studies

In their search for better treatments for breast, ovarian, and other cancers, young investigators Jennifer Guerriero, PhD, and Sarah Hill, MD, PhD, rely on a precious commodity — patient tissue samples obtained by surgeons in Dana-Farber’s Susan F. Smith Center for Women’s Cancers. Studies of these normal and cancerous tissues, which are collected, banked, and … Read more

Basic Science Discovery Leads to Clinical Trial for Patients with Chemotherapy-Resistant Form of Ovarian Cancer

Dana-Farber scientists recently uncovered a potential vulnerability in a form of ovarian cancer notoriously resistant to chemotherapy. Now they’ve opened a clinical trial involving a drug that targets that susceptibility in patients with the disease. The impetus for their research is a type of ovarian cancer with excess copies of the cyclinE1 gene (abbreviated CCNE1). … Read more

Scientists Identify Genes Tied to Increased Risk of Ovarian Cancer

Medically reviewed by Alexander Gusev, PhD A team of Dana-Farber scientists and their associates has identified 34 genes associated with an increased risk of developing earliest-stage ovarian cancer. The findings, published in the journal Nature Genetics, will both help identify women who have the highest risk of developing ovarian cancer and pave the way for identifying … Read more

Facing Ovarian Cancer, a Doctor Becomes the Patient

By Luisa Stigol, MD, FAAP I was a 74-year-old pediatrician in practice with a multi-specialty group associated with Boston Children’s Hospital. Forty years after becoming a doctor, I still loved learning new things and sharing them with my patients. Then I was diagnosed with ovarian cancer — and suddenly, a big wall separated me from … Read more

With precision cancer medicine, a success against endometrial cancer

In the annals of patients who have benefited from Dana-Farber and Brigham and Women’s Hospital’s (BWH) genomic sequencing program Profile, few involve a turnabout as dramatic as one recently reported in Gynecologic Oncology. Authored by nearly a dozen Dana-Farber and BWH faculty, the paper recounts the medical history of a 49-year-old Nebraska woman first diagnosed … Read more